Ursodeoxycholic acid for cystic fibrosis-related liver disease

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 12, 2014, Pages

  Cheng, Katharine ^a   Ashby, Deborah ^b   Smyth, Rosalind L ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; URSODEOXYCHOLIC ACID; CHOLAGOGUE;

BILIARY EXCRETION; BODY WEIGHT CHANGE; CHRONIC LIVER DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; LIVER FUNCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; BILE; CHILD; CHRONIC DISEASE; COMPLICATION; ENZYMOLOGY; LIVER; LIVER DISEASES; META ANALYSIS; PRESCHOOL CHILD; SECRETION (PROCESS);

ADOLESCENT; ADULT; BILE; CHILD; CHILD, PRESCHOOL; CHOLAGOGUES AND CHOLERETICS; CHRONIC DISEASE; CYSTIC FIBROSIS; HUMANS; LIVER; LIVER DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URSODEOXYCHOLIC ACID;

EID: 84925226804     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000222.pub3     Document Type: Review

References (35)

1. Colombo C, Allocca M, Quattrucci S, Traverso G, Farina S, Lucidi V, et al. Ursodeoxycholic acid for liver disease associated to cystic fibrosis: long-term follow-up of patients enrolled in the Italian multicenter trial [abstract]. Pediatric Pulmonology 2005;40(Suppl 28):343.
2. Colombo C, Battezzati PM, Santini B, Lapichino L, Quattrucci S, Lucidi V, et al. Ursodeoxycholic acid (UDCA) for liver disease associated with Cystic Fibrosis (CF): a double-blind multicenter trial [abstract]. Proceedings of the 18th European Cystic Fibrosis Conference; 1993 May 21-26; Madrid. 1993:W6.1.
3. Colombo C, Battezzatti PM, Podda M, Bettinardi N, Giunta A, and the Italian Group for the study of ursodeoxycholic acid in cystic fibrosis. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A double-blind multicenter trial. Hepatology 1996;23(6):1484-90.
4. Colombo C, Battezzatti PM, Santini B, Lapichino L, Quattrucci S, Lucidi V, et al. Treatment with ursodeoxycholic acid for patients with cystic fibrosis and liver disease. In: Escobar H, Baquero F, Suarez L editor(s). Clinical Ecology of Cystic Fibrosis. Elsevier Science Publishers BV, 1993:275-9.
5. Colombo C, Podda M, Battezzatti PM, Santini B, Lapichino L, Quattrucci S, et al. Ursodeoxycholic acid for cystic fibrosis-associated liver disease: Final report of a multicenter trial [abstract]. Hepatology 1993;18:142A.
6. Merli M, Bertasi S, Servi R, Diamanti S, Martino F, De Santis A, et al. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1994;19(2):198-203.
7. O' Brien S, Fitzgerald MX, Hegarty JE. A controlled trial of ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. European Journal of Gastroenterology & Hepatology 1992;4:857-63.
8. O'Brien S, Fitzgerald MX, Hegarty JE. Ursodeoxycholic acid treatment in cystic fibrosis related liver disease [abstract]. Gut 1992;33:S14.
9. O'Brien SM, Campbell GR, Burke AF, Maguire OC, Rowlands BJ, Fitzgerald MX, et al. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. European Journal of Gastroenterology & Hepatology 1996;8:477-83.
10. Bittner P, Posselt HG, Sailer T, Ott H, Magdorf K, Wahn U, et al. The effect of treatment with ursodeoxycholic acid in cystic fibrosis and hepatopathy: results of a placebo-controlled study. In: Paumgartner G, Stiehl A, Gerok W editor(s). Bile acids as therapeutic agents: From basic science to clinical practice (Falk Symposium, Vol 58). Lancaster: Kluwer Academic Publishers, 1991:345-8.
11. Bittner P, Seiler T, Ott H, Posselt HG, Margdorf K, Kawinkel M. Therapeutical approach of ursodeoxycholic acid in cystic fibrosis and hepatopathy [abstract]. Proceedings of the 16th Annual Meeting of the European Working Group for Cystic Fibrosis; 1989; Prague, Czechoslovakia. 1989:72.
12. Colombo C, Crosignani A, Assaisso M, Battezzati PM, Podda M, Giunta A, et al. Ursodeoxycholic acid therapy in cystic fibrosis- associated liver disease: A dose-response study. Hepatology 1992;16(4):924-30.
13. Colombo C, Setchell KDR, Podda M, Crosignani A, Assaisso ML, Giunta A. Ursodeoxycholic acid (UDCA) in CF associated liver disease (LD): A dose response study [abstract]. Proceedings of the 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen. 1991:140.
14. Narkewicz MR, Sokol RJ, Lear JL, Wagener JS, Accurso FJ. Effect of ursodeoxycholic acid (UDCA) therapy for CF liver disease on indirect tests of hepatic function [abstract]. Pediatric Pulmonology 1994;Suppl 10:342.
15. Van de Meeberg PC, Houwen RHJ, Sinaasappel M, Heijerman HGM, Bijleveld CHMA, Vanberge-Henegouwen GP. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scandinavian Journal of Gastroenterology 1997;32(4):369-73.
16. Van de Meeberg PC, VanBerge Henegouwen GP, The Dutch CF-UDCA Trial Group. Long-term follow-up of low dose versus high dose ursodeoxycholic acid (UDCA) in cholestasis related to cystic fibrosis (CF) [abstract]. Gut 1996;39(Suppl 3):A118.
17. Kapustina TJ, Kashirskaia NJ, Kapranov NI, Neudakhin EV. Effect of ursodeoxycholic acid on lipid metabolism in patients with cystic fibrosis [abstract]. Proceedings of the XIIIth International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm. 2000:132.
18. Lacaille F, Paradis K, Lenaerts C, Senechal L, Lepage G, Roy CC, et al. Ursodeoxycholic acid (UDCA) improves essential fatty acid (EFA) deficiency in cystic fibrosis [abstract]. Hepatology 1993;18(4, Pt 2):271A.
19. Lepage G, Paradis K, Lacaille F, Senechal L, Ronco N, Champagne J, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. Journal of Pediatrics 1997;130(1):52-8.
20. Spray C, Sinha B, Venkataraman M, Davies P, Ramani P, Weller P, et al. The role of ursodeoxycholic acid on histological changes in children with cystic fibrosis-liver disease - a prospective study [abstract]. Proceedings of the XIIIth International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm. 2000:132.
21. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16(3):707-14.
22. Bhardwaj S, Canlas K, Kahi C, Temkit M, Molleston J, Ober M, et al. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood. Journal of Clinical Gastroenterology 2009;43(9):858-64. [DOI: 10.1097/MCG.0b013e31819e8bbd]
23. Carty H. Abdominal radiology in cystic fibrosis. Journal of Royal Society of Medicine 1995;88(Suppl 25):18-23.
24. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
25. Erlinger S, Dumont M. Influence of ursodeoxycholic acid on bile secretion. In: Paumgartner G, Stiehl A, Barbara L, Roda E editor(s). Strategies for the treatment of hepatobiliary disease. Dordrecht: Kluwer Academic, 1990:35-42.
26. Frisancho AR. Anthropometric standards for the assessment of growth and nutritional status. Ann Arbor: University of Michigan Press 1990.
27. Leeuwen L, Fitzgerald DA, Gaskin KJ. Liver disease in cystic fibrosis. Paediatric Respiratory Review 2014;15(1):69-74. [DOI: 10.1016/j.prrv.2013.05.001]
28. O'Connor PJ, Southern KW, Bowler IM, Irving HC, Robinson PJ, Littlewood JM. The role of hepatobiliary scintigraphy in cystic fibrosis. Hepatology 1996;23(2):281-7.
29. Parisi GF, Di Dio G, Franzonello C, Gennaro A, Rotolo N, Lionetti E, et al. Liver disease in cystic fibrosis: an update. Hepatitis Monthly 2013;13(8):e11215. [DOI: 10.5812/hepatmon.11215]
30. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. New England Journal of Medicine 1991;324(22):1548-54.
31. Pharmacy Department, Royal Liverpool Children's Hospital NHS Trust. Personal communication December 2003.
32. Roda E, Bazzoli F, Labate AM. Ursodeoxycholic acid vs chenodeoxycholic acid as cholesterol gallstone-dissolving agents: a comparative randomized study. Hepatology 1982;2(6):804-10.
33. Tanner MS. Liver and biliary problems in cystic fibrosis. Journal of Royal Society of Medicine 1992;85(Suppl 19):20-4.
34. Cheng K, Smyth RL, Ashby D. Ursodeoxycholic acid in cystic fibrosis related liver disease: a systematic review. Journal of the Royal Society of Medicine 1997;90(Suppl 31):6-12.
35. Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: 10.1002/14651858.CD000222]